Advertisement
Australia markets closed

  • ALL ORDS

    7,898.90
    +37.90 (+0.48%)
     

  • AUD/USD

    0.6446
    +0.0009 (+0.14%)
     

  • ASX 200

    7,642.10
    +36.50 (+0.48%)
     

  • OIL

    81.84
    -0.85 (-1.03%)
     

  • GOLD

    2,397.20
    +8.80 (+0.37%)
     

  • Bitcoin AUD

    96,945.35
    -943.62 (-0.96%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Eagle Pharmaceuticals to Present at the William Blair 42nd Annual Growth Stock Conference

Eagle Pharmaceuticals, Inc.
·1-min read
Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc.

WOODCLIFF LAKE, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the William Blair 42nd Annual Growth Stock Conference as follows:

Date:

Thursday, June 9, 2022

 

 

Time:

9:40AM ET/8:40AM CT

 

 

Webcast:

Click Here

 

 

About Eagle Pharmaceuticals, Inc.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include vasopressin injection, PEMFEXY™, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM (Japan), and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

Investor Relations for Eagle Pharmaceuticals, Inc.:

Lisa M. Wilson        
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com